Below the belt

时间:2019-03-08 01:10:12166网络整理admin

A FRESH insight into why testicular cancer responds so well to chemotherapy could lead to more effective treatments for other tumours, say researchers in Britain. Beate Köberle of the Imperial Cancer Research Fund’s Clare Hall Laboratories and colleagues noticed that testicular cancer cells lack an enzyme called XPA, which repairs the damage to DNA caused by the anticancer drug cisplatin (Current Biology, vol 9, p 273). Using drugs to cut XPA levels in other types of tumour could make chemotherapy more effective,